We are live on ! Find out more
SPRY icon

ARS Pharmaceuticals
SPRY

187 hedge funds and large institutions have $1.48B invested in ARS Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 82 increasing their positions, 47 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more call options, than puts

Call options by funds: $11.1M | Put options by funds: $4.05M

167% more funds holding in top 10

Funds holding in top 10: 3 → 8 (+5)

74% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 47

54% more capital invested

Capital invested by funds: $960M → $1.48B (+$516M)

23% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 22

8.32% more ownership

Funds ownership: 77.73% → 86.06% (+8.3%)

2% more funds holding

Funds holding: 184 → 187 (+3)

Holders
187
Holders Change
+3
Holders Change %
+1.63%
% of All Funds
2.46%
Holding in Top 10
8
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+166.67%
% of All Funds
0.11%
New
27
Increased
82
Reduced
47
Closed
22
Calls
$11.1M
Puts
$4.05M
Net Calls
+$7.08M
Net Calls Change
+$8.95M

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$24.9M
2
SCA
Southpoint Capital Advisors
New York
+$24.7M
3
Citadel Advisors
Citadel Advisors
Florida
+$20.8M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$18.8M
5
Goldman Sachs
Goldman Sachs
New York
+$10.8M

Top Sellers

Rank Fund Capital Flow
1
LCS
Levin Capital Strategies
New York
-$12.6M
2
DM
Deerfield Management
New York
-$11.4M
3
CAM
Cormorant Asset Management
Massachusetts
-$7.21M
4
RA
Royce & Associates
New York
-$5.58M
5
NIP
Nicholas Investment Partners
California
-$5.15M
Name Holding Trade Value Shares
Change 		Change in
Stake
GI
176
GAMMA Investing
California
$5.15K +$404 +28 +10%
ACM
177
Aster Capital Management
United Arab Emirates
$4.68K -$40.7K -2,823 -91%
Bessemer Group
178
Bessemer Group
New Jersey
$4K – – –
RIL
179
Rothschild Investment LLC
Illinois
$2.88K +$866 +60 +57%
SCM
180
Sterling Capital Management
North Carolina
$2.32K +$1.18K +82 +161%
IA
181
IFP Advisors
Florida
$1.45K – – –
EP
182
Essential Partners
California
$995 +$822 +57 New
PFBT
183
Parkside Financial Bank & Trust
Missouri
$786 – – –
LFG
184
Larson Financial Group
Missouri
$558 +$462 +32 New
TWD
185
True Wealth Design
Ohio
$367 – – –
PS
186
Principal Securities
Iowa
$297 +$245 +17 New
EWA
187
EverSource Wealth Advisors
Alabama
$105 +$87 +6 New
ARC
188
Advisor Resource Council
Texas
– -$3.14M -249,230 Closed
TI
189
Trexquant Investment
Connecticut
– -$1.27M -100,769 Closed
DCM
190
DAFNA Capital Management
California
– -$1.2M -95,290 Closed
Squarepoint
191
Squarepoint
New York
– -$966K -76,824 Closed
DFCM
192
Dark Forest Capital Management
Puerto Rico
– -$711K -56,553 Closed
Simplex Trading
193
Simplex Trading
Illinois
– -$636K -44,092 Closed
Verition Fund Management
194
Verition Fund Management
Connecticut
– -$348K -27,681 Closed
CF
195
Corebridge Financial
Texas
– -$303K -24,109 Closed
HF
196
HRT Financial
New York
– -$299K -23,845 Closed
TC
197
TwinBeech Capital
New York
– -$273K -21,700 Closed
CM
198
Capula Management
Cayman Islands
– -$262K -20,791 Closed
CIBC Private Wealth Group
199
CIBC Private Wealth Group
Georgia
– -$247K -20,000 Closed
EGM
200
Engineers Gate Manager
New York
– -$234K -18,583 Closed
5 6 7
8
9

SPRY Hedge Fund Activity: Q2 2025 in Review

187 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q2 2025, worth a combined $1.48B — up 54% from $960M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new SPRY positions and 22 closed out — a net gain of 5 holders — while 82 added to existing stakes and 47 trimmed.

The largest buyer was Adage Capital Partners, opening a new position worth an estimated $24.9M. The largest seller was Levin Capital Strategies, cutting an estimated $12.6M.

  • 187 institutional investors held ARS Pharmaceuticals (SPRY) as of Q2 2025, up from 184 in Q1 2025.
  • Funds reported $1.48B of ARS Pharmaceuticals stock for Q2 2025, up 54% quarter-over-quarter.
  • 27 funds opened new ARS Pharmaceuticals positions in Q2 2025 and 22 closed out, a net change of +5 holders.
  • The largest ARS Pharmaceuticals buyer in Q2 2025 was Adage Capital Partners, an estimated $24.9M added.
  • The largest ARS Pharmaceuticals seller in Q2 2025 was Levin Capital Strategies, an estimated $12.6M sold.

Based on aggregated 13F filings for Q2 2025.